Now Available!

2024 Product Guide

Receive a copy of our current research models and services product guide.

Download Now

Quantify any protein, in any sample, with any modification, without antibodies

Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.

Learn More

Supporting your critical research with our inflation reduction model program

Reduce costs with our complimentary sample for evaluation in your lab.

Claim Your Offer

In vivo solutions for Developmental and Reproductive Toxicology and Juvenile Animal Studies

Learn More

Count on our expertise in IBD animal models for your next in vivo study

Discover More

Sample our new Biosecure Plus™ SOPF models

Learn More

Discover our array of highly characterized PDX models

Discover More

Expect More From Your Discovery, Development and Research Models Partner

in-vivo-1 In Vivo Services In Vivo Services From discovery pharmacology and toxicology, through regulated enabling safety assessment studies, our team has the in vivo and analytical capabilities to deliver a variety of flexible solutions adaptable to your needs. icon-histology Histology Histology Our industry-leading histology laboratories support your discovery and nonclinical development projects with a wide range of services. From tissue processing to digital analysis, our team delivers the quality you expect.   icon-histology-pathology Pathology Pathology Access our world-class anatomical, clinical, and medical device pathology team that provides services from histochemistry to digital pathology including IHC, IF, and ISH to stereology, and more.  icon-drug-metabolism-bioanalysis-pk DMPK DMPK From hit-to-lead to lead optimization through candidate selection, our in vitro, in vivo, and bioanalytical teams offer the fit-for-purpose solutions you need at any stage of development to help you analyze, answer, and advance.  icon-consulting Consulting Consulting Our experts deliver the insights you deserve to get the answers you need, whether in DMPK data analysis, biomarker analysis, or bioequivalence studies. research-models Research Models Research Models Paired with the most comprehensive range of research models in the industry, we offer the experience, quality, and consistency that is essential to your success.  icon-model-services Research Model Services Research Model Services Our research model services group provides high-quality support services worldwide, including genetically engineered models and services (GEMS), contract breeding services, surgical services, and more. icon-teklad Teklad Diet and Bedding Teklad Diet and Bedding What comes out of your research depends in large part on what goes into your research models. Ensuring study models have the most appropriate laboratory animal diet, bedding, and enrichment is critical to maintaining consistent, reliable data. 

Explore Our Full Offering of Services and Products


Discovery and Development 

Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.  


Research Models and Services 

Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.  

The Latest From Inotiv

Society of Toxicology (SOT)

March 10-14, 2024 Salt Lake City, UT Booth #917 Join Inotiv scientists at SOT held March 10-14, 2024, at the Salt Palace Convention Center in Salt Lak...

American Association for Cancer Research (AACR)

April 5-10, 2024 San Diego, CA Booth #3729 The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from p...

Workshop on Recent Issues in Bioanalysis (WRIB)

May 6-10, 2024 San Antonio, TX Booth #TBD Each year WRIB program provides you with novel case studies and emerging approaches because it is the only p...

Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

February 07, 2024 – First quarter fiscal 2024 revenue up 10.3% to $135.5 mi...

Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024

January 29, 2024 WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a lea...

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

December 11, 2023 — Fiscal year 2023 revenue up 4.5% to $572.4 millio...

On-demand Webinar

Not All IBD Models Are Created Equally

How Differences Between Experimental IBD Models Can Impact Your Drug Development Program

Scientific Poster

Comparative Evaluation of Different Plating Methodologies and Sources of Induced S9 Metabolic Activation on the Mutagenic Potential of N-Nitrosodipropylamine Using the Ames Test

Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now